XBiotech Inc (XBIT)
XBiotech Inc. is a healthcare company focused on biotechnology research and development. The company works on discovering and developing True Human monoclonal antibodies for the treatment of a range of diseases. Its development pipeline includes product candidates aimed at inflammatory and infectious conditions, as well as interleukin-1 alpha therapies being studied for several medical uses, including cancer, stroke, heart attack, and arthritis. These programs are also associated with biological processes such as tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Incorporated in 2005, XBiotech is headquartered in Austin, Texas, and its common stock is listed on NASDAQ under the symbol XBIT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-XBIT
|
$3.52
|
60.1% Upside
|
Bargain
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-1.7x
|
0.5x
|
—
|
68.597 M
|
-48.386 M
|
0.0%
|
74.9%
|
32.4
|
—
|
105.5%
|
